The development and technical validation of new immunoassays for ProteoMediX’ biomarker as well as the clinical testing were published in PLOS ONE. In conclusion, the report provides evidence that the newly developed method shows improved performance in diagnosing prostate cancer.

http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0181557

‍